Unified Parkinson's disease rating scale

Last updated
Unified Parkinson's disease rating scale
Purposeused to follow the longitudinal course of Parkinson's disease

The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease. The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease. [1]

Contents

The UPDRS is made up of these sections: [2]

These are evaluated by interview and clinical observation. Some sections require multiple grades assigned to each extremity.

Clinicians and researchers alike use the UPDRS and the motor section in particular to follow the progression of a person's Parkinson's disease. Scientific researchers use it to measure benefits from a given therapy in a more unified and accepted rating system. Neurologists also use it in clinical practice to follow the progression of their patients' symptoms in a more objective manner. [3]

Following the UPDRS scores over time provides insight into the patient's disease progression. For instance Michael J. Fox's symptoms started with a slight tremor, so his motor score would have been less than 10. For most patients, the "mentation, behavior and mood" scores increase later in the disease, but a subset exists for whom those symptoms develop early on. [4]

Similar rating scales

Other rating scales for Parkinson's disease are the Hoehn and Yahr scale and Schwab and England activities of daily living scale, although both of these measures are currently included within the UPDRS in modified format.

MDS-UPDRS

In 2007, the Movement Disorder Society (MDS) published a revision of the UPDRS, known as the MDS-UPDRS. [5] The revision became desirable after an MDS-sponsored Task Force on Rating Scales for Parkinson's Disease highlighted the limitations of the original UPDRS. [6] Two major limitations include the lack of consistent anchor among subscales and the low emphasis on the nonmotor features of PD. [5] The modified UPDRS retains the four-scale structure with a reorganization of the various subscales. Score ranges from 0 to 260, [7] [8] with 0 indicating no disability and 260 indicating total disability. The scales are:

Each item has 0–4 ratings: 0 (normal), 1 (slight), 2 (mild), 3 (moderate), and 4 (severe). [10]

Related Research Articles

<span class="mw-page-title-main">Essential tremor</span> Movement disorder that causes involuntary tremors

Essential tremor (ET), also called benign tremor, familial tremor, and idiopathic tremor, is a medical condition characterized by involuntary rhythmic contractions and relaxations of certain muscle groups in one or more body parts of unknown cause. It is typically symmetrical, and affects the arms, hands, or fingers; but sometimes involves the head, vocal cords, or other body parts. Essential tremor is either an action (intention) tremor—it intensifies when one tries to use the affected muscles during voluntary movements such as eating and writing—or it is a postural tremor, present with sustained muscle tone. This means that it is distinct from a resting tremor, such as that caused by Parkinson's disease, which is not correlated with movement.

<span class="mw-page-title-main">Parkinsonism</span> Medical condition

Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability. These are the four motor symptoms found in Parkinson's disease (PD) – after which it is named – dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and many other conditions. This set of symptoms occurs in a wide range of conditions and may have many causes, including neurodegenerative conditions, drugs, toxins, metabolic diseases, and neurological conditions other than PD.

<span class="mw-page-title-main">Apathy</span> State of indifference, or the suppression of emotions

Apathy is a lack of feeling, emotion, interest, or concern about something. It is a state of indifference, or the suppression of emotions such as concern, excitement, motivation, or passion. An apathetic individual has an absence of interest in or concern about emotional, social, spiritual, philosophical, virtual, or physical life and the world. Apathy can also be defined as a person's lack of goal orientation. Apathy falls in the less extreme spectrum of diminished motivation, with abulia in the middle and akinetic mutism being more extreme than both apathy and abulia.

<span class="mw-page-title-main">Deep brain stimulation</span> Neurosurgical treatment involving implantation of a brain pacemaker

Deep brain stimulation (DBS) is a surgical procedure that implants a neurostimulator and electrodes which sends electrical impulses to specified targets in the brain responsible for movement control. The treatment is designed for a range of movement disorders such as Parkinson's disease, essential tremor, and dystonia, as well as for certain neuropsychiatric conditions like obsessive-compulsive disorder (OCD) and epilepsy. The exact mechanisms of DBS are complex and not entirely clear, but it is known to modify brain activity in a structured way.

The Hoehn and Yahr scale is a commonly used system for describing how the symptoms of Parkinson's disease progress. It was originally published in 1967 in the journal Neurology by Margaret Hoehn and Melvin Yahr and included stages 1 through 5. Since then, a modified Hoehn and Yahr scale was proposed with the addition of stages 1.5 and 2.5 to help describe the intermediate course of the disease. It has been shown that HY stage discrimination can be automated, even with patients who cannot support themselves.

In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief from the symptoms.

<span class="mw-page-title-main">Dihydroergocryptine</span> Chemical compound

Dihydroergocryptine (DHEC), sold under the brand names Almirid and Cripar among others, is a dopamine agonist of the ergoline group that is used as an antiparkinson agent in the treatment of Parkinson's disease. It is taken by mouth.

<span class="mw-page-title-main">Dopamine dysregulation syndrome</span> Medical condition

Dopamine dysregulation syndrome (DDS) is a dysfunction of the reward system observed in some individuals taking dopaminergic medications for an extended length of time. It typically occurs in people with Parkinson's disease (PD) who have taken dopamine agonist medications for an extended period of time. It is characterized by problems such as addiction to medication, gambling, or sexual behavior.

<span class="mw-page-title-main">Parkinson's disease</span> Long-term degenerative neurological disorder

Parkinson's disease (PD), or simply Parkinson's, is a chronic degenerative disorder of the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease progresses, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson's disease dementia is common in advanced stages.

The applause sign is a behavioural indicator, relevant to neurodegenerative conditions, characterised by a patient’s inability to execute the same number of hand claps as demonstrated by an examiner.

Signs and symptoms of Parkinson's disease are varied. Parkinson's disease affects movement, producing motor symptoms. Non-motor symptoms, which include dysautonomia, cognitive and neurobehavioral problems, and sensory and sleep difficulties, are also common. When other diseases mimic Parkinson's disease, they are categorized as parkinsonism.

Pridopidine is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent Sigma-1 Receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

<span class="mw-page-title-main">Pardoprunox</span> Antiparkinsonian compound researched for the treatment of depression and anxiety disorders

Pardoprunox (INN) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.

The Lee Silverman Voice Treatment – LOUD is a treatment for speech disorders associated with Parkinson's disease (PD). It focuses on increasing vocal loudness and is delivered by a speech therapist in sixteen one-hour sessions spread over four weeks. A derivative of this treatment, known as LSVT BIG, is used in treating movement aspects of Parkinson's disease.

The International Cooperative Ataxia Rating Scale (ICARS) is an outcome measure that was created in 1997 by the Committee of the World Federation of Neurology with the goal of standardizing the quantification of impairment due to cerebellar ataxia. The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment.

The REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) is a specific questionnaire for rapid eye movement behavior disorder (RBD) developed by Stiasny-Kolster and team, to assess the most prominent clinical features of RBD. It is a 10-item, patient self-rating instrument with short questions to be answered by either 'yes' or 'no'. The validity of the questionnaire was studied by researchers and they have observed it to perform with high sensitivity and reasonable specificity in the diagnosis of RBD.

Gait variability seen in Parkinson's Disorders arise due to cortical changes induced by pathophysiology of the disease process. Gait rehabilitation is focused to harness the adapted connections involved actively to control these variations during the disease progression. Gait variabilities seen are attributed to the defective inputs from the Basal Ganglia. However, there is altered activation of other cortical areas that support the deficient control to bring about a movement and maintain some functional mobility.

The Parkinson's Foundation is a national organization that funds research and provides educational resources to Parkinson’s disease patients and caregivers. The Parkinson's Foundation was established in 2016 through the merger of the National Parkinson Foundation and the Parkinson's Disease Foundation. The Parkinson's Foundation has headquarters in Miami and New York City, in addition to 17 chapters throughout the United States.

Parkinson's disease dementia (PDD) is dementia that is associated with Parkinson's disease (PD). Together with dementia with Lewy bodies (DLB), it is one of the Lewy body dementias characterized by abnormal deposits of Lewy bodies in the brain.

Sue Ellen Leurgans is a biostatistician known for her work on disorders of human movement, including those caused by occupational injury and Parkinson's disease. She is a professor of neurological sciences at the Rush University Medical Center in Chicago.

References

  1. ↑ Ramaker, Claudia; Marinus, Johan; Stiggelbout, Anne Margarethe; van Hilten, Bob Johannes (1 September 2002). "Systematic evaluation of rating scales for impairment and disability in Parkinson's disease". Movement Disorders. 17 (5): 867–876. doi:10.1002/mds.10248. PMID   12360535. S2CID   2562332.
  2. ↑ Comprehensive pharmacy review, Leon Shargel, 6th edition, p. 998.
  3. ↑ "Frequently Asked Questions". Parkinson's Disease Foundation. 23 March 2009. Archived from the original on 19 July 2011. Retrieved 31 January 2011.
  4. ↑ Rosenbaum, Richard B. (2006). Understanding Parkinson's Disease: A Personal and Professional View. Greenwood Publishing Group. ISBN   978-0-275-99166-1.
  5. 1 2 Goetz, Christopher G.; Fahn, Stanley; Martinez-Martin, Pablo; Poewe, Werner; Sampaio, Cristina; Stebbins, Glenn T.; Stern, Matthew B.; Tilley, Barbara C.; Dodel, Richard; Dubois, Bruno; Holloway, Robert; Jankovic, Joseph; Kulisevsky, Jaime; Lang, Anthony E.; Lees, Andrew; Leurgans, Sue; LeWitt, Peter A.; Nyenhuis, David; Olanow, C. Warren; Rascol, Olivier; Schrag, Anette; Teresi, Jeanne A.; Van Hilten, Jacobus J.; LaPelle, Nancy (1 January 2007). "Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan". Movement Disorders. 22 (1): 41–47. doi: 10.1002/mds.21198 . PMID   17115387.
  6. ↑ Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (July 2003). "The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations". Movement Disorders. 18 (7): 738–50. doi:10.1002/mds.10473. PMID   12815652. S2CID   1759369.
  7. ↑ Sheshadri, Veena; Rowland, Nathan C.; Mehta, Jigesh; Englesakis, Marina; Manninen, Pirjo; Venkatraghavan, Lashmi (2017). "Comparison of General and Local Anesthesia for Deep Brain Stimulator Insertion: A Systematic Review". Canadian Journal of Neurological Sciences. 44 (6): 697–704. doi: 10.1017/cjn.2017.224 . ISSN   0317-1671. PMID   28920562.
  8. 1 2 3 4 5 Balestrino, Roberta; Hurtado-Gonzalez, Carlos Alberto; Stocchi, Fabrizio; Radicati, Fabiana Giada; Chaudhuri, K. Ray; Rodriguez-Blazquez, Carmen; Martinez-Martin, Pablo (2019-11-27). "Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS)". npj Parkinson's Disease. 5 (1): 26. doi:10.1038/s41531-019-0097-1. ISSN   2373-8057. PMC   6881347 . PMID   31798050.
  9. 1 2 3 4 Skorvanek, Matej; Martinez-Martin, Pablo; Kovacs, Norbert; Rodriguez-Violante, Mayela; Corvol, Jean-Christophe; Taba, Pille; Seppi, Klaus; Levin, Oleg; Schrag, Anette; Foltynie, Thomas; Alvarez-Sanchez, Mario; Arakaki, Tomoko; Aschermann, Zsuzsanna; Aviles-Olmos, Iciar; Benchetrit, Eve (2017). "Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration". Movement Disorders Clinical Practice. 4 (4): 536–544. doi:10.1002/mdc3.12476. PMC   6174385 . PMID   30363418.
  10. ↑ "Parkinson's Disease Diagnostic Criteria". BMJ. Retrieved 8 May 2012.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.